126 related articles for article (PubMed ID: 38630926)
1. Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
Br J Dermatol; 2024 Apr; 190(5):e58. PubMed ID: 38630926
[No Abstract] [Full Text] [Related]
2. Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
Mukhtar AB; Morgan HJ; Gibbs A; Davies GE; Lovatt C; Patel GK
Br J Dermatol; 2024 Apr; 190(5):729-739. PubMed ID: 38288865
[TBL] [Abstract][Full Text] [Related]
3. Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.
Sung GJ; Choi HK; Kwak S; Song JH; Ko H; Yoon HG; Kang HB; Choi KC
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):76-81. PubMed ID: 27793752
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in
Hartman ML; Rozanski M; Osrodek M; Zalesna I; Czyz M
Lab Invest; 2017 Feb; 97(2):217-227. PubMed ID: 28067893
[TBL] [Abstract][Full Text] [Related]
5. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
Liu Q; Zhu H; Tiruthani K; Shen L; Chen F; Gao K; Zhang X; Hou L; Wang D; Liu R; Huang L
ACS Nano; 2018 Feb; 12(2):1250-1261. PubMed ID: 29370526
[TBL] [Abstract][Full Text] [Related]
7. Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF(V) (600R) mutation.
Sabater-Marco V; García-Rabasco A; García-García JA; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1197-8. PubMed ID: 25763513
[No Abstract] [Full Text] [Related]
8. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF
Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R
J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827
[TBL] [Abstract][Full Text] [Related]
10. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.
Hartsough EJ; Basile KJ; Aplin AE
Mol Cancer Res; 2014 May; 12(5):795-802. PubMed ID: 24520098
[TBL] [Abstract][Full Text] [Related]
12. Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.
Ide M; Koba S; Sueoka-Aragane N; Sato A; Nagano Y; Inoue T; Misago N; Narisawa Y; Kimura S; Sueoka E
Pathol Oncol Res; 2017 Jan; 23(1):181-188. PubMed ID: 27766572
[TBL] [Abstract][Full Text] [Related]
13. [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].
Molnár E
Magy Onkol; 2020 Mar; 64(1):76-78. PubMed ID: 32181767
[TBL] [Abstract][Full Text] [Related]
14. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
15. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
16. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
17. Analysis of BRAF mutation in primary and metastatic melanoma.
Libra M; Malaponte G; Navolanic PM; Gangemi P; Bevelacqua V; Proietti L; Bruni B; Stivala F; Mazzarino MC; Travali S; McCubrey JA
Cell Cycle; 2005 Oct; 4(10):1382-4. PubMed ID: 16096377
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
19. ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells.
Chang F; Zhang Y; Mi J; Zhou Q; Bai F; Xu X; Fisher DE; Sun Q; Wu X
Cancer Sci; 2018 Nov; 109(11):3428-3437. PubMed ID: 30168234
[TBL] [Abstract][Full Text] [Related]
20. Detection of BRAF gene mutation in primary choroidal melanoma tissue.
Malaponte G; Libra M; Gangemi P; Bevelacqua V; Mangano K; D'Amico F; Mazzarino MC; Stivala F; McCubrey JA; Travali S
Cancer Biol Ther; 2006 Feb; 5(2):225-7. PubMed ID: 16410717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
